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Abstract 
Neuroblastoma is the most common childhood extra-cranial solid tumor. In high-risk cases, 
many of which are characterized by amplification of MYCN, outcome remains poor. Mutations in 
the p53 (TP53) tumor suppressor are rare at diagnosis, but evidence suggests that p53 function 
is often impaired in relapsed, treatment-resistant disease. To address the role of p53 loss-of-
function in the development and pathogenesis of high-risk neuroblastoma, we generated a 
MYCN-driven genetically engineered mouse model in which the tamoxifen-inducible p53ERTAM 
fusion protein was expressed from a knock-in allele (Th-MYCN/Trp53KI). We observed no 
significant differences in tumor-free survival between Th-MYCN mice heterozygous for Trp53KI 
(n=188) and Th-MYCN mice with wild-type p53 (n=101). Conversely, the survival of Th-
MYCN/Trp53KI/KI mice lacking functional p53 (n=60) was greatly reduced. We found that Th-
MYCN/Trp53KI/KI tumors were resistant to ionizing radiation (IR), as expected. However, 
restoration of functional p53ERTAM reinstated sensitivity to IR in only 50% of Th-
MYCN/Trp53KI/KI tumors, indicating the acquisition of additional resistance mechanisms. Gene 
expression and metabolic analyses indicated that the principal acquired mechanism of 
resistance to IR in the absence of functional p53 was metabolic adaptation in response to 
chronic oxidative stress. Tumors exhibited increased antioxidant metabolites and upregulation 
of glutathione S-transferase pathway genes, including GSTP1 and GSTZ1, which are 
associated with poor outcome in human neuroblastoma. Accordingly, glutathione depletion by 
buthionine sulfoximine together with restoration of p53 activity re-sensitized tumors to IR. Our 
findings highlight the complex pathways operating in relapsed neuroblastomas and the need for 
combination therapies that target the diverse resistance mechanisms at play.
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Introduction 
p53 is a critical tumor suppressor that performs a diverse range of functions including induction 
of apoptosis, senescence and DNA repair in response to genotoxic stress. Deregulation of its 
activity is associated with tumor initiation and progression as well as resistance to therapy. 
Recent in vivo evidence indicates that the role of p53 as a tumor suppressor is independent of 
its canonical role as a cell cycle, senescence and pro-apoptosis regulator, and may be due to 
other p53-dependent activities such as maintenance of DNA stability and metabolic adaptation 
(1). In the last decade, a role for p53 in metabolic adaptation has been identified (2,3), often 
activated by metabolic stress induced by low oxygen levels or nutrient scarcity (3). This leads to 
changes in several metabolic mechanisms affecting energy homeostasis such as glycolysis, 
down-regulation of reactive oxygen species (ROS), oxidative phosphorylation (OXPHOS), β-
oxidation and gluconeogenesis (4). However, to date there is no direct evidence demonstrating 
an advantage in tumor survival or growth in vivo due to metabolic alterations induced by p53 
loss-of-function. 
Neuroblastoma is the most common extracranial pediatric solid tumor and amplification of 
the MYCN gene is a predictor of high-risk disease. Treatment options for high-risk patients 
include intensive cytotoxic chemotherapy and surgical resection, myeloablative autologous stem 
cell transplantation, radiotherapy, and intensive multimodal therapy. Although most high-risk 
patients initially respond to therapy, a majority of these patients will relapse with treatment-
resistant disease. Approximately 50% of relapsed tumors are associated with p53 loss-of-
function, mainly through alterations to the p53 pathway. In contrast to other MYC-driven 
cancers, such as medulloblastoma (5) and lymphoma, mutation of genes in the p53 pathway is 
rare at diagnosis (6), implying that selection for p53 pathway deficiency occurs following 
treatment. Additional mechanisms such as epigenetic alterations and metabolic adaptation have 
also been implicated in aggressive neuroblastoma (7-11). To better understand the role of p53 
in the development of high-risk therapy-resistant neuroblastoma, we generated a MYCN-driven 
genetically engineered mouse (GEM) model with inducible p53 loss-of-function.
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Materials and Methods 
In vivo studies 
All experimental protocols were monitored and approved by The Institute of Cancer Research 
Animal Welfare and Ethical Review Body, in compliance with the UK Home Office Animals 
(Scientific Procedures) Act 1986, the United Kingdom National Cancer Research Institute 
guidelines for the welfare of animals in cancer research (12), and the ARRIVE guidelines (13). 
Th-MYCN mice (129X1/SvJ-Tg(Th-MYCN)41Waw/Nci) have been described previously (14). 
The Trp53KI/KI mice were kindly provided by G.I. Evan (15) and crossed with Th-MYCN animals 
into a background of the 129X1/SvJ-Tg(TH-MYCN)41Waw/Nci (for more than 15 generations). 
Transgenic Th-MYCN/Trp53KI animals with palpable tumor were allocated to treatment or control 
groups. Restoration of wild-type p53 was achieved by administration of chow containing 
tamoxifen at 400 mg/kg to provide a daily dose of approximately 64 mg/kg. Animals were 
monitored twice a week by palpation for detectable tumors (>5 mm) and were sacrificed upon 
detection of a tumor larger than 15mm diameter. Mice were allowed access to sterilized food 
and water ad libitum. 
In vivo imaging 
Multi-slice 1H MRI was performed on a 7T horizontal bore microimaging system (Bruker 
Instruments) using a 3 cm birdcage coil. Anesthesia was induced using a gaseous mixture of 
2% isoflurane/oxygen (v/v). Core body temperature was maintained by warm air blown through 
the magnet bore. T2-weighted coronal and transverse images were acquired from twenty 
contiguous 1 mm thick slices through the mouse abdomen, using a rapid acquisition with 
refocused echoes (RARE) sequence with 4 averages of 128 phase encoding steps over a 3x3 
cm field of view, an echo time (TE) of 36 ms, a repetition time (TR) of 4.5 s and a RARE factor 
of 8. The resolution was 0.234 x 0.234 mm/pixel and the acquisition time was 3 minutes 24 
seconds. Volumetric data was analysed using in-house software (ImageView) (16). 
Immunoblot analysis 
Total protein was extracted from equal size tumor pieces in SDS sample buffer using 
Precellys24. The following antibodies were used to detect protein levels (all from Cell Signaling): 
phospho-p53 (9284), cleaved caspase 3 (9661), caspase 3 (9665), p-ATM (5883p), phospho-
ATR (2853p), phospho-CHK2 (2661p), GAPDH (8884s), γ-H2AX (9718x), and tubulin (2128L). 
Also used were antibodies against p19ARF (Novus Biologicals, 5-c3-1), and horseradish 
peroxidase (HRP) conjugated-p53 (R&D system, HAF1355). Proteins were detected using 
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HRP-conjugated anti-mouse and anti-rabbit antibodies (Dako), ECL Ultra (TMA-6) (Lumigen) 
and imaged using a Fujifilm LAS-4000 system. 
Immunohistochemistry 
Tumors were processed using a ASP300S tissue processor (Leica) according to the 
manufacturer’s instructions. Sections were deparaffinized and dehydrated through Histo-Clear 
and graded alcohol series, rinsed for 5 min in tap water, boiled for 5min in 1% citric buffer and 
left to cool to RT. Endogenous enzyme activity was blocked by 1% H2O2 for 20min followed by 3 
washes in ddH2O. For mouse antibodies we used the M.O.M kit (Vector BMK-2202), for rabbit, 
the following protocol was used; blocking for >1h in PBS 0.01% Triton, 5% BSA, 1st antibody 
was incubated at RT overnight 1:100-1:500, washed in TBS, 2nd Biotinylated Anti Rabbit was 
incubated at RT for >2h (1:500), 3rd avidin HRP conjugated (A2664) (1:1000) 1hr RT. Antibody 
solution; PBS 0.01% Triton, 1% BSA. Sections were stained for 1-5 min using Vector Imm 
PACT DAB (SK-4105). We used the following antibodies; CD31 (ab28364), cleaved caspase 3 
(Cell Signaling 9661), neurofilament-L (NF-L) (Cell Signaling 2837), Tuj-1 (R&D systems, 
BAM1195). Sections were counter-stained with hematoxylin and eosin. Immunofluorescence 
staining was performed using Invitrogen Alexa Fluor 488 goat anti-rabbit. Images were captured 
by confocal microscopy (LSM700, LSM T-PMT) and processed by ZEN2012 (Zeiss) software. 
Real-time PCR 
Total RNA was isolated from tumor tissue using the miRNAeasy minikit (Qiagen) and cDNA 
prepared using Superscript II Reverse Transcriptase (Life Technologies). Quantitative PCR 
(QT-PCR) was performed in triplicate using Taqman Gene Expression mix (Life Technologies) 
and gene-specific primers for Cdkn1a (Mm04205640), Puma (Mm00519268), Noxa-1 
(Mm00549172), Bax (Mm00432051) and Actb (Mm00607939) (Life Technologies). Relative 
expression was calculated according to the ΔΔCt relative quantification method against the 
average expression of control tumors. 
Hypoxia 
Tumor hypoxia was assessed as previously described (16,17). Briefly, tumor-bearing mice 
received 60 mg/kg i.p. of the hypoxia marker pimonidazole hydrochloride (Hypoxyprobe). After 
45 min, tumors were rapidly excised, snap-frozen and stored in liquid nitrogen. Sections were 
either stained using Hypoxyprobe-1 plus FITC-conjugated mouse monoclonal antibodies 
(1:100), or HRP conjugated rabbit anti-FITC (Hypoxyprobe-1 Plus Kit). 
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Quantitation of reactive oxygen species 
Freshly excised tumor samples (~20mg) were incubated with 10µM CellROX Oxidative Stress, 
(Molecular probes, C10444) for 1hr. Subsequently single cells were washed twice with PBS and 
fixed with 4% PFA for 1h, washed in PBS and acquired by FACS (BD-LSRII) using FACSDiva 
software (BD Biosciences). Sample were analysed by FlowJo (FlowJo LLC). 
Glutathione assay 
Glutathione was measured in fresh tumor samples using the GSH-Glo glutathione assay 
(Promega). Luciferase levels were normalized to tissue mass. 
Statistical Analysis 
Sample were compared using one-way ANOVA or two way ANOVA as indicated and post-hoc 
Bonferroni multiple comparison tests using GraphPad Prism; p values < 0.05 were considered 
as statistically significant. 
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Results 
Th-MYCN transgenic mice display a normal p53 response 
During tumorigenesis the expression or activity of checkpoint regulators, including p53, are 
often suppressed. We sought to establish whether this is also the case in our GEM model of 
MYCN-driven neuroblastoma (Th-MYCN). To this end we tested the levels of the p53 upstream 
regulator p19Arf in matched tumor and spleen tissues and found similar protein expression levels 
(Fig. S1A), suggesting that the p53 pathway is intact. We also examined p53 activation following 
stress by exposing Th-MYCN tumor-bearing mice to cytotoxic ionizing radiation (IR). The p53 
pathway was induced by IR as evidenced by increased levels of transcriptionally active p53 
phosphorylated at serine 15 (p-p53Ser15) in tumors, spleen and thymus (Fig. S1B), as well as an 
increase in the p53 target gene Cdkn1a (p21Cip1/Waf1) (Fig. S1C). Furthermore, we found tumor-
specific upregulation of the pro-apoptotic gene Bbc3 (Puma), but not the pro-apoptotic genes 
Pmaip1 (Noxa) or Bax (Fig. S1C, D). Both the cyclin-dependent kinase inhibitor p21 and Puma 
are well-characterized effectors of p53-mediated growth arrest and apoptosis. Consistent with 
this, apoptosis was enhanced as evidenced by the presence of cleaved caspase3 (CC3) in the 
tumor and the thymus (Fig. S1B and S2). Induction of DNA damage was demonstrated by the 
presence of phosphorylated histone gamma-H2AX (γ-H2AX), primarily in the spleen and the gut 
(Fig. S2). Taken together, these results suggest that Th-MYCN mice are representative of p53 
wild-type (WT) human neuroblastoma. 
p53 loss-of-function leads to increased tumor penetrance in Th-MYCN hemizygous mice 
In order to evaluate p53 loss-of function in neuroblastoma, we crossed Th-MYCN mice (in which 
expression of a human MYCN transgene is directed by a rat tyrosine hydrolase (Th) promoter to 
neural crest cells during early development) (14) with a GEM model conditionally deficient for 
functional p53 (Fig. 1A) (15). Here, the endogenous Trp53 gene is replaced with a knock-in 
allele (Trp53KI) encoding a 4-hydroxytamoxifen (4-OHT)-regulatable p53ERTAM fusion protein. In 
the presence of 4-OHT (a metabolite of tamoxifen, Tam), the hormone-binding domain of the 
estrogen receptor (ER) is released from its inhibitory conformation and p53ERTAM is translocated 
to the nucleus. Homozygous Th-MYCN transgenic mice display 100% penetrance (18), 
developing tumors within seven to eight weeks of birth, whereas only 16% of hemizygous Th-
MYCN transgenic mice with wild-type (WT) Trp53 (Th-MYCN/Trp53WT/WT) developed tumors by 
21 weeks of age with a median latency of 62 days (Fig. 1B, Table S1). Thus penetrance and 
latency in the Th-MYCN GEM model are dependent on transgene dosage and in this study only 
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heterozygous Th-MYCN mice were used. While Th-MYCN mice heterozygous for MYCN and 
Trp53KI (Th-MYCN/Trp53KI/WT) displayed a moderate increase in penetrance to 27% with no 
significant decrease in tumor-free survival, this increased dramatically to 75% for mice 
homozygous for Trp53KI (Th-MYCN/Trp53KI/KI). No littermates lacking Th-MYCN, either 
heterozygous or homozygous for Trp53KI, developed neuroblastomas by 200 days. While 
Trp53KI homozygosity increased penetrance, this had no effect on either latency or tumor 
growth rate as measured by volumetric magnetic resonance imaging (MRI) (Fig. 1C). 
To test whether the increased tumor incidence in Th-MYCN/Trp53KI/WT mice was due to a 
mutation in the WT Trp53 allele, we sequenced exons 5-9 (corresponding to the p53 DNA 
binding domain) in Th-MYCN/Trp53WT/WT (n = 16), Th-MYCN/Trp53KI/WT (n = 12) and Th-
MYCN/Trp53KI/KI (n = 11) tumors. We found only one mutation arising in the Th-
MYCN/Trp53KI/WT cohort (Table S2), supporting the notion that increased tumor penetrance in 
Th-MYCN/Trp53KI/WT mice is not caused by inactivation of the remaining WT Trp53 allele. We 
also examined whether post-natal Tam-induced restoration of functional p53 could affect tumor 
penetrance, latency and growth rate. We administered Tam to tumor-bearing mice aged 50-80 
days as well as to 30-day old mice, a timepoint at which tumors are not yet detectable. We 
found that restoration of functional p53ERTAM had no effect on tumor growth rate or penetrance 
in Th-MYCN/Trp53KI/KI mice (Fig. S3 A, B). 
Pathological investigations in Th-MYCN/Trp53KI transgenic mice revealed that they 
developed paravertebral, thoracic or abdominal solid tumors, consistent with a parasympathetic 
origin in common with the Th-MYCN GEM model. Immunohistochemical analysis revealed that 
all Th-MYCN/Trp53KI tumors stained positive for the neuroblastoma markers Tuj-1 and 
neurofilament-L (NF-L) (Fig. 1D). Furthermore, in agreement with the parasympathetic origin of 
the Th-MYCN tumors (19), histopathological analysis revealed an increase in the percentage of 
pups positive for neuroblast hyperplasia in the Th-MYCN/Trp53KI/KI compared to Th-
MYCN/Trp53WT/WT (Fig. S4). Thus our results suggested that p53 loss-of-function interacts with 
aberrant expression of MYCN at an early stage of neuroblastoma tumorigenesis. However, p53 
deficiency did not affect latency or tumor growth rate. 
MYCN-driven neuroblastomas deficient for p53 are resistant to apoptosis induced by IR 
Given that p53 pathway alterations are associated with relapsed/treatment-resistant 
neuroblastoma, we tested whether p53 deficiency conferred an anti-apoptotic advantage to 
tumors in Th-MYCN/Trp53KI/KI mice. External beam radiotherapy is widely used in 
neuroblastoma treatment following induction chemotherapy and surgery, although a period of 
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remission is often followed by subsequent relapse in high-risk cases (20). To examine a role for 
p53 deficiency in treatment-resistant neuroblastoma, we exposed Th-MYCN/Trp53WT/WT and Th-
MYCN/Trp53KI/KI tumor-bearing mice to IR in the presence or absence of tamoxifen. In Th-
MYCN/Trp53WT/WT tumors, 5Gy IR induced apoptosis 5.5 hours post-IR as measured by the 
presence of pyknotic nuclei in 90-95% of the cells (Fig. 2A). By contrast, Th-MYCN/Trp53KI/KI 
tumors were found to be resistant to IR-induced apoptosis. This resistance was maintained in 
some individual animals upon Tam-induced restoration of functional p53ERTAM with responses 
ranging from IR resistance to complete response (Fig. 2A). IR also failed to significantly improve 
survival in Th-MYCN/Trp53KI/K allografts, providing evidence for intrinsic resistance to IR in 
these tumors (Fig. 2B). While the degree of activation of p53ERTAM was similar (as measured by 
nuclear p-p53Ser15 and induction of Cdkn1a expression) post IR and Tam administration, this did 
not correlate with induction of apoptosis. Furthermore, tumors that showed a similar degree of 
p53 activation displayed differences in apoptotic response (Fig. 2C, D). Pharmacokinetic 
analysis (LC-MS/MS) of Tam levels supported these findings with results showing a significant 
correlation between levels of Tam and 4-OHT but no apoptotic response (Fig. 2E). Collectively 
these results suggest that p53 loss-of-function confers an anti-apoptotic advantage to tumors in 
response to cytotoxic IR, and that a fraction of Th-MYCN/Trp53KI/KI tumors develop resistance to 
restoration of p53 function. 
p53 loss-of-function leads to upregulation of the GSH antioxidant metabolic pathway in 
MYCN-driven neuroblastoma 
To characterize the mechanisms underlying resistance to IR in Th-MYCN/Trp53KI/KI tumors, we 
performed Affymetrix expression microarray analysis. Surprisingly, few genes (only 38 protein-
coding transcripts) were altered across the Th-MYCN/Trp53KI/KI cohort of tumor samples 
compared with Th-MYCN/Trp53WT/WT tumors. This is may be due to a high degree of inter-
tumoral heterogeneity in the pattern of gene expression among Th-MYCN/Trp53KI/KI tumors as 
revealed by hierarchical clustering (Fig. 3A) and principal component analysis (Fig. 3B). While 
Th-MYCN/Trp53WT/WT tumors cluster together tightly, this is not replicated in the Th-
MYCN/Trp53KI/KI cohort. Thus, to identify pathways that may be altered in common among Th-
MYCN/Trp53KI/KI tumors, we analysed gene expression in individual Th-MYCN/Trp53KI/KI tumors 
against the Th-MYCN/Trp53WT/WT control cohort. Differentially expressed genes were combined 
and analysis of the composite gene list revealed seven significantly altered pathways between 
the groups. (Table S3). Of these, we identified the glutathione metabolism pathway, which is 
associated with drug resistance (21-23), to be differentially regulated (Table S3). An 
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examination of genes encoding components of the glutathione metabolism pathway in individual 
tumors revealed upregulation in 50% of Th-MYCN/Trp53KI/KI tumors. Furthermore, the 
glutathione S-transferase (GST) family, including GSTZ1 and GSTP1, represented the largest 
group (7 out of 17 genes) (Table 1). Glutathione and antioxidants have been shown to affect 
tumor initiation and drug resistance (23) and overexpression of GSTP1 (24) and GSTZ1 
correlate with poor survival in neuroblastoma patients (Fig. 3C). 
p53 deficiency leads to an increase in the GSH pool in response to chronic oxidative 
stress in MYCN-driven neuroblastoma 
Glutathione S-transferase (GST) catalyzes the conjugation of the reduced form of glutathione 
(GSH) to xenobiotic substrates or unstable molecules such as hydrogen peroxide or other 
reactive oxygen species (ROS) for the purpose of detoxification (Fig. 3D). To examine whether 
the upregulation of GST is correlated with changes in the GSH redox cycle, we performed 
metabolic analysis using gas-chromatography mass spectrometry (GC-MS). We identified 12 
metabolites that were significantly altered between Th-MYCN/Trp53WT/WT and Th-
MYCN/Trp53KI/KI tumors (Table 2). Consistent with our gene expression data, the glutathione 
pool was increased by 3.7-fold in Th-MYCN/Trp53KI/KI tumors, together with a 4.3-fold decrease 
in glycine, a glutathione precursor (Table 2). The increase in GSH in Th-MYCN/Trp53KI/KI tumors 
was confirmed using the GSH-Glo glutathione assay (Fig. 3E). Interestingly, p53 restoration did 
not reverse this metabolic adaptation, with high GSH levels maintained in Th-MYCN/Trp53KI/KI 
tumors. Upregulation of the GSH antioxidant metabolic pathway in p53-deficient MYCN-driven 
neuroblastoma suggested an increased requirement for detoxification of GST substrates, such 
as derivatives of ROS that are implicated in tumorigenesis, disease progression and drug-
induced resistance (25). Furthermore, c-MYC over-expression and p53 loss-of-function have 
previously been shown to be associated with an alteration in ROS levels (2,26-28). Consistent 
with these results, we found a significant increase in ROS-positive cells in Th-MYCN/Trp53KI/KI 
tumors (mean of 64%) compared with Th-MYCN/Trp53WT/WT tumors (mean of 14%) (Fig. 4A–C). 
Furthermore, in agreement with the data shown in Fig. 2, restoration of p53ERTAM activity 
reduced the percentage of ROS-positive cells in ~50% of tumors (Fig. 4C). This suggests that 
enhanced ROS levels may be regulated (either directly or indirectly) by p53 in a fraction of Th-
MYCN/Trp53KI/KI tumors. As noted above, this was not associated with a decrease in tumor 
growth or improved overall survival (Fig. S3). Evidence for the presence of increased oxidative 
stress in Th-MYCN/Trp53KI/KI tumors was supported by the finding of enhanced staining for 8-
hydroxyguanosine (8-OHdG), a modified base that occurs in DNA due to attack by hydroxyl 
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radicals (29). (Fig. 4D). ROS levels can also be increased by hypoxia and staining with the 
hypoxia marker pimonidazole, revealed that Th-MYCN/Trp53KI/KI tumors contained increased 
perinecrotic hypoxic regions (Fig. 4E, F). Increased ROS has been reported to lead to damage 
to enzymes, membranes and DNA (29,30) but despite enhanced 8-OHdG staining (Fig 4D), we 
found no significant changes in the levels of DNA damage markers (p-CHEK2 and γ-H2AX) 
between untreated Th-MYCN/Trp53WT/WT and Th-MYCN/Trp53KI/KI tumors (Fig. S5). 
Our results suggest that resistance to IR in Th-MYCN/Trp53KI/KI mice may be due to 
metabolic adaption to chronic oxidative stress through up-regulation of GST pathway genes and 
increased levels antioxidant metabolites. This implied that the depletion of the GSH pool could 
resensitize IR-resistant p53 deficient neuroblastoma cells. Thus, we treated tumors with 
buthionine sulfoximine (BSO), an inhibitor of GSH synthesis that targets glutamate cysteine 
ligase (GCL), the first enzyme of the cellular GSH biosynthetic pathway (Fig. 3D). We implanted 
Th-MYCN/Trp53KI/KI primary tumor cells subcutaneously into 129X1/SvJ-Tg Th-MYCN negative 
mice. Consistent with our findings in the Th-MYCN/Trp53KI/KI GEM model of spontaneous 
neuroblastoma, 50% of the allografted tumors in which p53 activity was restored by the addition 
of Tam displayed resistance to IR and a higher Ki-67 proliferative index (Fig. 5A). However, 
importantly, this resistance was abolished in the presence of BSO (Fig. 5B, C).
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Discussion 
In this study we have demonstrated that p53 deficiency combines with aberrant expression of 
MYCN to drive neuroblast hyperplasia and increased neuroblastoma penetrance. Restoration of 
functional p53ERTAM prior to tumors reaching detectable size or during later stages failed to alter 
tumor growth or penetrance. These findings suggest that p53 has an important role in the early 
stages of neuroblastoma tumorigenesis in Th-MYCN transgenic mice. Furthermore, p53 loss-of-
function gives rise to tumors that can acquire growth and survival mechanisms that are resistant 
to the reintroduction of functional p53. This is in stark contrast to a medulloblastoma GEM 
model driven by expression of MYCN and p53 deficiency, GTML/Trp53KI/KI (GTML; Glt1–
tTA/TRE–MYCN–Luc), where restoration of functional p53ERTAM by Tam led to increased 
survival and inhibition of tumor growth (5). Other transgenic models of p53 loss-of-function do, 
however, develop tumors that display partial resistance to the restoration of functional p53ERTAM 
including lymphoma where a requirement for induction of the oncogenic signaling sensor p19ARF 
was identified (31). Additionally, p53 restoration in K-Ras induced NSCLC failed to induce tumor 
regression but diminished the proportion of high-grade tumors (32). 
Recent results have suggested that the outcome of p53 restoration in established tumors 
is highly context-dependent. There is now evidence that the tumor suppressor function of p53 
may be due to maintenance of genomic stability as well as metabolic and oxidative balance 
rather than simply its canonical role as a transcriptional activator of cell-cycle inhibitory and pro-
apoptotic effectors such as p21, PUMA, and NOXA (1,3). Consistent with these findings, we 
found that tumors with p53 loss-of-function displayed elevated ROS. Three characteristics of 
Th-MYCN/Trp53KI/KI tumors could contribute to the increased levels of ROS: MYCN expression, 
hypoxia, and p53 loss-of-function. MYCN-dependent metabolic adaptation has been shown to 
result in upregulation of glycolytic metabolism, which is associated with increase in ROS 
production (7,33). Hypoxia, on the other hand, can generate ROS via mitochondrial complex III 
(34) and p53 has been shown to regulate ROS and, in turn, to be regulated by ROS in a 
context-dependent manner (35). The low level of ROS in Th-MYCN/ Trp53WT/WT compared with 
Th-MYCN/Trp53KI/KI tumors suggests that MYCN alone cannot be the only driver and that loss of 
p53 is also required. A number of direct p53 targets involved in the antioxidant pathway have 
been identified such as MnSOD, sestrins (Sesn1-3), NRF2, ALDH4 (aldehyde dehydrogenase 
4), GLS2 (glutaminase 2), TIGAR, and tumor protein p53-inducible nuclear protein 1 
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(TP53INP1) (2,36). However, p53 also has a context-dependent pro-oxidant function and can 
transcriptional upregulate genes with strong pro-oxidant properties including PIG1–13 (p53-
inducible genes 1–13) (37). The dual pro-oxidant and anti-oxidant roles of p53 suggest a 
delicate interplay between p53 and ROS in normal cells and in the absence of p53 one might 
expect to see the changes in the ROS-redox equilibrium identified in this study. Thus the 
combination of MYCN expression, p53 loss-of-function and hypoxia leading to elevated ROS in 
Th-MYCN/Trp53KI/KI tumors may account for the resistance to cell death in the absence of 
functional p53ERTAM. However the lack of cell death upon restoration of functional p53ERTAM 
indicates that other mechanisms arose to compensate for the increased oxidative stress. 
There are several reducing mechanisms that regulate ROS-driven oxidative stress by 
transferring an unstable electron to a stable molecule. Among them is the glutathione pathway, 
where glutathione peroxidase reduces hydrogen peroxide to water while it oxidizes GSH to form 
dithiol (GSSH). Several genes from the GSH pathway are regulated by p53, which can down-
regulate glutathione peroxidase 1 (GPX1) and glutaredoxin 3 (GRX3) to reduce ROS (38,39). A 
compensatory increase in the GSH pathway in the absence of functional p53 is supported by 
our results with Th-MYCN/Trp53KI/KI tumors exhibiting significant changes in the glutathione 
pathway, further confirmed by an increase in the GSH pool as measured by multiple assays. In 
addition to the direct detoxification of hydrogen peroxide by GSH, GSH can also be conjugated 
to xenobiotic substrates for the purpose of detoxification of the metabolites produced within the 
cell by oxidative stress. This reaction is catalyzed by GST. Interestingly, we found that 7/12 of 
the altered genes in glutathione metabolism pathway are from the GST family. Up-regulation of 
GSTs is associated with chemo-resistance and appears to represent an adaptive response to 
increased cellular damage and an important protective mechanism (33,35,40). This role of GST 
is consistent with the resistance to IR exhibited by Th-MYCN/Trp53KI/KI tumors, even after 
restoration of functional p53ERTAM. GSTP1 is transcriptionally regulated by MYCN (24) and, 
alongside GSTZ1, high expression of these genes are linked with poor outcome in 
neuroblastoma (http://r2.amc.nl). Consistent with this, high levels of GSH are associated with 
resistance to chemotherapeutic and targeted therapies, including those used in frontline 
treatment of neuroblastoma such as cyclophosphamide, as well as relapsed disease such as 
irinotecan and temozolomide (41-44). 
The continuing high relapse rate and poor survival for high-risk neuroblastoma patients 
makes the development of new therapeutic approaches an urgent priority. While direct 
mutations to p53 are a rare event in de novo cases of neuroblastoma (6), examination of the 
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p53 pathway has underlined its role in the pathogenesis of high-risk neuroblastoma (45-50). The 
role of p53 loss-of-function in the pathogenesis of untreated neuroblastomas has thus far not 
been elucidated. Our study, however, strongly suggests that p53 plays an important role in the 
maintenance of redox homoeostasis. Thus in the absence of p53 tumors may metabolically 
adapt to acquire pro-survival characteristics that nullify the canonical pro-apoptotic effects of 
p53. We therefore suggest that strategies to target neuroblastomas with defective p53 function 
using reactivation of p53 through inhibition of the MDM2/p53 interaction would not be successful 
in a proportion of cases. Here, pharmacologic depletion of the GSH pool together with 
reactivation of p53 represents an alternative strategy. Furthermore, high GSH pool levels or 
elevated expression of GSTP1, GSTZ1 or other glutathione pathway genes could serve as 
biomarkers for the stratification patients. In this study we used BSO, an inhibitor of GCL, to 
deplete the GSH pool but specific inhibitors of GSTP1 such as 8-methoxypsoralen are currently 
under development (51). The use of agents to deplete the GSH pool in combination with 
conventional therapeutics or molecularly-targeted drugs thus warrants further study in high-risk 
neuroblastoma. 
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Table 1. Altered expression of genes in the glutathione pathway among individual
Th-MYCN/Trp53KI/KI tumors versus Th-MYCN/Trp53WT/WT tumors. 
Gene Sample 
 82078 83997 84834 28914 69306 72224 26857 
Gstm1 +      + 
Gstm7 +      + 
Gstm2       + 
Gstm4 +       
Gstp1    +  + + 
Gstt1       + 
Gstz       + 
Mgst3 +       
Gstm3 +      + 
Rrm2    +  +  
Anpep        
Gclc +       
Gpx3 +   +  +  
Gstt2       + 
Gstk1       + 
Mgst1       + 
Mgsta3       + 
 
Table 2. Analysis of metabolites in p53 deficient tumors. 
Metabolite KIKI:WT/WT Ratio p-value 
Alanine 0.480 1.23E-02 
Valine 0.496 3.26E-02 
Threonine 0.544 3.90E-02 
Glycine 0.233 2.38E-02 
Succinate 0.631 4.47E-02 
PEP 0.538 3.52E-02 
Hypotaurine 0.382 4.50E-02 
Hypoxanthine 1.924 2.81E-02 
3-GP 0.531 4.33E-02 
L-ascorbic acid 0.397 3.18E-02 
Ribose-5-phosphate 0.651 3.13E-02 
GSH pool 3.761 1.66E-02 
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Figure Legends 
Figure1. p53 deficiency leads to increased tumor penetrance in MYCN-driven 
neuroblastoma. 
A. Th-MYCN transgenic mice were crossed with a GEM model comprising a knock in of the 
Trp53 allele (Trp53KI) expressing tamoxifen-regulatable p53ERTAM. 
B. Kaplan-Meier survival curves for Th-MYCN/Trp53WT/WT (n = 101), Th-MYCN/Trp53KI/WT (n = 
188; ns, p = 0.06) or Th-MYCN/Trp53KI/KI (n = 60; ****, p < 0.0001) transgenic mice as indicated. 
****, p < 0.0001; log-rank test. 
C. Tumor volume change (relative to day 0) determined by MRI at day 4 for Th-
MYCN/Trp53WT/WT (n = 9) Th-MYCN/Trp53KI/WT (n = 7) and Th-MYCN/Trp53KI/KI mice (n = 8). 
D. Representative images of tumor sections from Th-MYCN/Trp53WT/WT, Th-MYCN/Trp53KI/WT 
and Th-MYCN/Trp53KI/KI tumors subjected to H&E and immunohistochemical staining for the 
marker of apoptosis cleaved caspase 3 (CC3), and neuroblastoma markers Tuj1 and NF-L 
(brown). Cell nuclei were counterstained with hematoxylin. Scale bar: 50µM. 
Figure 2. Tumors deficient for p53 exhibit p53-dependent and independent treatment 
resistance. 
A. Mice bearing 5mm palpable tumors were placed on normal or tamoxifen diet for 5 days 
followed by whole-body irradiation (IR, 5 Gy) or mock treatment. Irradiated Th-
MYCN/Trp53WT/WT tumors treated (n = 6) or untreated (n = 4) with tamoxifen (Tam), and 
irradiated Th-MYCN/Trp53KI/KI tumors treated (n = 6) or untreated (n = 7) with Tam were 
analysed to quantify dead cells as indicated by H&E (left) and percentage values (right). Scale 
bar: 100 µM. *p = 0.03, unpaired t-test. 
B. Tumor free survival analysis of Th-MYCN/Trp53KI/KI allografts from primary tissue, control (n = 
8) and irradiated (n = 8). 
C. Immunofluorescence analysis of phosphorylated p53Ser15 (p-p53) of Th-MYCN/Trp53KI/KI 
irradiated Th-MYCN/Trp53KI/KI tumors treated (n = 6) or untreated (n = 7) with Tam. Lower panel 
shows cells nuclear counterstained with DAPI. Values for percentage nuclear phosphorylated 
p53Ser15 and apoptotic cells are indicated and highlighted by a black border in 2A. Scale bar: 20 
µM. 
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D. RT-PCR analysis of Cdkn1a expression relative to Actb. Cdkn1a expression was evaluated 
in Th-MYCN/Trp53WT/WT untreated tumors (n = 5) or tumors treated with IR (n = 6), as well as 
Th-MYCN/Trp53KI/KI untreated tumors (n = 5) or tumors treated with IR minus Tam (n = 5) or 
plus Tam (n = 4). ****p < 0.0001; *p = 0.04; unpaired t-test. 
E. Correlation plot between the intratumoral concentrations of 4-OHT and tamoxifen expressed 
in nM (left, r = 0.86, n = 8, p < 0.01) and correlation plot between intratumoral concentrations of 
4-OHT and percentage of dead cells (right, r = 0.01, n = 8, p = 0.97). 
Figure 3. Transcriptomic analysis of p53 deficient tumors reveals upregulation of GSH 
antioxidant pathway genes and an increased GSH pool and purine metabolism 
A-D. Affymetrix mouse transcriptome array analysis of Th-MYCN/Trp53WT/WT (n = 4) and Th-
MYCN/Trp53KI/KI (n = 8) tumors. 
A. Hierarchal clustering. 
B. Principal component analysis of signal intensities. 
C. Overall survival of human neuroblastoma patients according to low or high expression of 
GSTP1 and GSTZ1 (http://r2.amc.nl, Versteeg-88 database of human neuroblastoma samples, 
GEO Series GSE16476). 
D. Schematic representation of the glutathione metabolic pathway. 
E. Analysis of GSH using the GSH-Glo glutathione assay in samples from MYCN/Trp53WT/WT 
tumors (n = 4), untreated Th-MYCN/Trp53KI/KI tumors (n = 6), or Th-MYCN/Trp53KI/KI tumors 
treated with tamoxifen (Tam) (n = 4). *p = 0.02; unpaired t-test. 
Error bars represent mean ± SD. 
Figure 4. Th-MYCN/Trp53KI/KI tumors exhibit chronic oxidative stress. 
A. Fluorescence staining for NF-L expression and the presence of reactive oxygen species 
(ROS) in Th-MYCN/Trp53KI/KI tumor cells. Scale bar: 50 µM. 
B. Histogram of ROS intensity as stained by CellROX Green in Th-MYCN/Trp53KI/KI, Th-
MYCN/Trp53WT/WT, or unstained negative control cells as indicated. Grey bar represents the 
intensity threshold for ROS positivity. 
C. Flow cytometric analysis of ROS-positive cells in Th-MYCN/Trp53WT/WT tumors with (n = 7) or 
without (n = 9 tamoxifen or Th-MYCN/Trp53KI/KI tumors with (n = 6) or without (n = 4) tamoxifen. 
****p < 0.0001; unpaired t-test. 
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D. Staining for the oxidative stress marker 8-hydroxyguanosine (8-OHdG) in Th-
MYCN/Trp53KI/KI tumors. Scale bar: 100 µM. 
E. Top, Fluorescence measurement of pimonidazole adduct formation in tumors from Th-
MYCN/Trp53WT/WT (n = 7) or Th-MYCN/Trp53KI/KI (n = 7) mice. Data points represent the mean 
area for each individual tumor *p = 0.04; unpaired t-test. Bottom, representative fluorescence 
images from Th-MYCN/Trp53WT/WT and Th-MYCN/Trp53KI/Ki tumors as indicated. 
F. H&E and immunohistochemical co-staining with CD31 and Hypoxyprobe in Th-
MYCN/Trp53WT/WT and Th-MYCN/Trp53KI/K tumors. Scale bar: 100 µM. 
Error bars represent mean ± SD. 
Figure 5. Depletion of the GSH pool restores sensitivity to IR. 
A-C. Mice bearing allografts derived from Th-MYCN/Trp53KI/K tumors were untreated (n = 4), 
treated with IR (n = 4), tamoxifen (Tam) (n = 4) or buthionine sulfoximine (BSO) (n = 4). Mice 
were injected bilaterally with tumor cells and 6-8 tumors analyzed per group. Scale bar: 50 µM. 
A. H&E and immunohistochemical staining for cell proliferation (Ki-67) in Th-MYCN/Trp53KI/KI 
allografts responsive or resistant to treatment with IR and Tam as indicated. 
B. Quantitative histopathological determination of cell death in Th-MYCN/Trp53KI/KI allografts 
treated with IR, Tam and/or BSO as indicated. *p = 0.03, unpaired t-test (one-tailed). 
C. Total GSH levels in Th-MYCN/Trp53KI/KI allografts treated with IR and Tam, with or without 
BSO as indicated. *p = 0.04, unpaired t-test (one-tailed). 
Error bars represent mean ± SD. 
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